Rilonacept, sold under the brand name Arcalyst, is a medication used to treat cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome, and Muckle–Wells syndrome; deficiency of interleukin-1 receptor antagonist; and recurrent pericarditis. [1][2][3] Rilonacept is an interleukin 1 inhibitor.

ARCALYST ® (rilonacept) is an interleukin-1 blocker indicated for: Treatment of Recurrent Pericarditis (RP) and reduction in risk of recurrence in adults and pediatric patients 12 years and older.

ARCALYST ® (rilonacept) is an interleukin-1 blocker indicated for: Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and pediatric patients 12 years and older.

FDA has approved Arcalyst (rilonacept) injection to treat recurrent pericarditis and reduce the risk of recurrence in adults and children 12 years and older.

2024年5月1日 · Arcalyst (rilonacept) is used to treat Cryopyrin-Associated Periodic Syndromes, Deficiency of Interleukin-1 Receptor Antagonist, and recurrent pericarditis. Includes Arcalyst side effects, interactions and indications.

ARCALYST (rilonacept) is an interleukin-1 blocker indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and...

Rilonacept is used to treat some of the symptoms of rare genetic conditions such as Familial Cold Auto-inflammatory Syndrome (FCAS) or Muckle-Wells Syndrome (MWS).

Rilonacept is a medication that treats recurrent pericarditis. This condition causes inflammation of the sac around your heart. A healthcare provider can give you this injection or they’ll teach you …

2024年6月3日 · ARCALYST® (rilonacept) is an interleukin-1 blocker indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS) in …

2024年5月28日 · Rilonacept is a prescription medication used for the treatment of Cryopyrin Associated Periodic Syndromes, Pericarditis and for maintenance of remission of deficiency of interleukin-1 receptor antagonist (DIRA) .